Best practice learnings from Moving Pharma Forward, Asia

Suat Toh Head of Sales APAC
suat.toh@envirotainer.com

Envirotainer has a strong focus on Asia, which is perhaps the most innovative region for pharmaceutical production at present. To serve our partners, clients and other stakeholders in the industry pharma logistic industry, we have hosted four (4) Moving Pharma Forward events in Asia this autumn, in Mumbai, Shanghai, Seoul and Tokyo. Here is a snapshot of what was discussed during the events.

Moving Pharma Forward in Mumbai

On September 13th, 2019, the Envirotainer India team hosted a Moving Pharma Forward event in Mumbai. About a hundred guests attended, with about half of the attendees from pharmaceutical companies and the other half from airlines, freight forwarders and ground-handlers.

Apart from sessions held by Envirotainer experts, a number of external speakers shared their experiences. For example, Mr. Sunil Menon from multinational pharmaceutical and biotechnology company USV shared his experiences of shipping biosimilar products and how to evaluate the transportation chain and determining responsibilities. Mr. Alan Fernandes from Sanofi talked about ensuring integrity and realizing cost-savings by a streamlined process through the Mumbai gateway.

mpf-mumbai-evemt-1200x800.jpg©Envirotainer

Attendees could also participate in a tour of Envirotainer’s new station in Mumbai to get a hands-on experience. The tour was coordinated by Hoon Tien Ho, from Envirotainer’s Global Service Network team, and Allied Aviation, Envirotainer’s ground handler in Mumbai.

Shanghai

On September 17th, Envirotainer’s China team hosted the first Moving Pharma Forward event in China in Shanghai, with many attendees from the pharmaceutical industry as well as freight forwarders and airlines.

Mr. David Zhou from Henlius shared his experience of validating Envirotainer’s solution during a trial shipment from Shanghai to London with Emirates Airlines, which showcased the seamless process of coordination between partners to support their upcoming NPI launch. At a panel discussion with representatives from Lilly, Shanghai Pudong Airport, freight forwarder Chevalier AOC and Envirotainer, the different perspectives of each stakeholder were discussed and how each decision made will impact everyone. Envirotainer experts also held workshops about visibility of the cold chain and the importance of having the right knowledge for good practices.

Seoul

On October 29th, Envirotainer hosted its Moving Pharma Forward event in Seoul. The attendees came from a large number of freight forwarders, airlines and pharmaceutical companies.

Korea Bio Association kick-started the event by briefing the audience about the Korean biopharmaceutical industry outlook for 2020. Mr. Michael Lopez from Medytox shared his insights about how to best meet the increasing requirements for economical, safe and documented temperature-controlled shipping solutions with detailed comparisons between active and passive solutions. Ms. Minji Jang from Hanmi Pharmaceutical shared her experiences of handling both Envirotainer’s active containers and passive solutions for their various products in different temperature requirements. Attendees showed great interest in Hanmi’s presentation on how to cope with cold chain challenges.

Mr. Seunghyun Hong from GC Pharma shared his experience of validating Envirotainer’s solution during shipping qualification from Incheon to Chicago with Korean Airlines. Also, experts from Envirotainer held workshops about cold chain continuous improvement through data analytics and how to enhance and improve cold chain shipment SOPs to meet the stringent regulations of the global market.

e2-container-mumbai-1200x800.jpg©Envirotainer

Tokyo

On October 31st, 2019, Envirotainer’s Japan team hosted Moving Pharma Forward in Tokyo with attendees from pharmaceutical companies, airlines and freight forwarders.

Apart from seminars held by Envirotainer experts, external partners held sessions to share their experiences. Mr. Matsunaga from Chugai Pharmaceutical Co. outlined an implementation process of qualification in new commercial business, and how pharmaceutical companies should proceed through a Design Qualification (DQ), Operational Qualification (OQ) and Performance Qualification (PQ) to establish SOP’s to mitigate risks in the global cold chain.

Mr. Hiroshi Ohyama from Mitsubishi Tanabe Pharma emphasized that there are three important factors for establishing quality management of a global cold chain:

  1. Understanding the other industries (e.g. airlines and forwarders),
  2. From the EHS (Environment, Health and Safety) and sustainability, we need to build a workflow in the appropriate distribution while caring for the environment and workers, and
  3. Go onsite (stop assuming and check by yourself).

Also, Envirotainer experts held presentations about cold chain continuous Improvement through data analytics and transparency during the transportation.

About Moving Pharma Forward

Envirotainer has hosted Moving Pharma Forward events across the globe for several years. The overall objective is to share industry insights and best practices and to strengthen cooperation between all stakeholders that are involved in establishing a safe and predictable pharmaceutical cold chain.

Envirotainer has a strong focus on Asia with local experts in place who can assist customers with knowledge from all over the world. Our Moving Pharma Forward events in Asia are part of our mission to bring stakeholders together to improve cooperation and execution of cold chain transportation.

Need help?

Contact Us

Whether you would like to know more about our services or to book an Envirotainer unit, there are many ways to get in touch with us. Contact one of our colleagues for a free consultation and see how we can help you balance quality versus cost. 

Related Articles

Total Landed Cost and sustainability

How pharma can save money and be friendlier to the planet

In the pharma industry, approximately 90% of all carbon emissions are generated in the manufacturing phase. The biggest positive impact on carbon emissions the secure cold chain can have is therefore to ensure that every single dose that is manufactured reaches the patient securely and on time.

Different alternatives for temperature-controlled transport

Breakthrough research in various medical fields, such as gene editing, stem cell technology and regenerative medicine, has led to an increased demand for temperature-controlled transport. High-end, specialized medicine is often produced in low volumes with no backup stock and thus, delivering these sensitive products safely across the globe has become a mounting logistical challenge. Selecting a secure and reliable logistics solution has accordingly become all the more important.

Reinventing the procurement process of pharma logistics

With the growing number of sensitive drugs, how can procurement keep transport costs under control while still adhering to necessary quality requirements?

Stay Connected with Our Newsletter!

Join our newsletter for the latest on products, services, events, and sustainability efforts!

🔹 Get product updates 🔹 Discover new services 🔹 Stay informed about upcoming events 🔹 Learn about our sustainability efforts 🔹 Other important updates

Subscribe Now